SA
CLDX icon

Scarborough Advisors’s Celldex Therapeutics CLDX Stock Holding History

Scarborough Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$190 – 239
2026
Q1 		$190 Hold
6
– – ﹤0.01% 709
2025
Q4 		$163 Hold
6
– – ﹤0.01% 433
2025
Q3 		$155 Hold
6
– – ﹤0.01% 447
2025
Q2 		$122 Buy
+6
New +$117 ﹤0.01% 441
2024
Q3 		– Sell
-6
Closed -$222 – 181
2024
Q2 		$222 Hold
6
– – ﹤0.01% 408
2024
Q1 		$252 Hold
6
– – ﹤0.01% 380
2023
Q4 		$238 Buy
+6
New +$176 ﹤0.01% 683

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scarborough Advisors's CLDX Position: Q2 2026 in Review

Scarborough Advisors sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 6 shares — an estimated $190 sold.

Scarborough Advisors first reported a position in CLDX in Q4 2023 and held it in 7 quarters. The position peaked at $252 in Q1 2024. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Scarborough Advisors reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Scarborough Advisors sold 6 Celldex Therapeutics shares in Q2 2026, an estimated $190.
  • Scarborough Advisors first reported a position in Celldex Therapeutics in Q4 2023 and held it in 7 quarters.
  • Scarborough Advisors's Celldex Therapeutics position peaked at $252 in Q1 2024.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Scarborough Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.